BREAKING: Inside $12B… | Sourcery Newsletter Summary

1. Key Themes

Theme 1: De-Extinction Is an Engineering Problem, Not a Research Problem — and That Reframe Is the Entire Business

Lamm founded Colossal with no biology background, deliberately treating extinction as a systems engineering challenge. This operator's mindset — owning the full stack rather than outsourcing to academics — is what generated proprietary data, IP, and spinout companies as byproducts.

"Extinction is a systems model. Genetic engineering from taking a 73,000-year-old skull and going to puppies is a systems model."

"What he brought was the software operator's instinct to own the entire stack, which is why Colossal runs ancient DNA extraction, computational genomics, cloning, and animal operations under one roof rather than farming pieces out to academic partners."

Theme 2: The Real Investment Thesis Is a Genome Engineering Toolkit, Not the Animals

De-extinction is the brand. The actual asset is the toolkit — genome editing at scale, full DNA synthesis, and artificial womb technology — with applications far beyond bringing back extinct species, spanning cancer, drug discovery, invasive species eradication, agriculture, and human fertility.

"I think genome engineering at scale and full DNA synthesis at scale and artificial wombs at scale have an application that's, like, insane."

"I do think that we are one of the most undervalued companies in the world, 'cause I truly do. The ability to preserve, engineer and direct life on a planetary scale, in all species, I think is a pretty important skill set for humanity."

Theme 3: AI × Biology Is Repricing in Real Time — Astromech Is Positioned at the Center

Astromech is training on 3.8 billion years of biological history to predict biological change before it happens — spanning drug resistance, pathogen spread, disease risk, and food security. On August 19, the day before this interview published, Moderna and Merck reported the first positive Phase 3 for an AI-designed personalized cancer vaccine, sending Moderna shares up 177%, repricing the entire category.

"It is truly exploding. It's like you're gonna see this like Precambrian explosion of new drugs and new therapies that all come from AI-assisted drug design and discovery."

"Biology runs the world and historically, we have only reacted to it. Every genome carries a record of what changed, when it changed, and the tradeoffs that followed, but almost none of that history is readable at scale today."

Theme 4: Spinout-as-Strategy — Colossal Is Building a Life Sciences Holding Company

Colossal has deliberately structured itself to spin out technologies that exceed its mission perimeter rather than expand the core brand or pursue obvious commercial adjacencies. This is a capital-efficient portfolio strategy — the parent company captures equity value in spinouts while maintaining brand clarity and mission focus.

"Our technologies can be applied to human, and we can spin them out and license them, but we won't do the human work here."

"We don't wanna have Colossal launches a hair solution, and then people are like, is that mammoth shit that people are putting on us? We never wanted that."

Three companies have already spun out: Form Bio (computational life sciences, $30M Series A), Breaking (plastic degradation), and Astromech (AI biology, $3.8B valuation). Artificial womb technology is next, targeted for 2027 with human fertility applications.

Theme 5: Invasive Species as an Overlooked Half-Trillion Dollar Market for Biotech

Colossal has already built a gene drive solution for invasive species — organisms engineered to spread sterility through a target population — and sized the problem at $500B globally. The federal alternative for the New World screwworm alone runs $1.5B over eight years. Colossal's model says they could eradicate it in six to seven months.

"Invasive species is like a half trillion dollar problem globally. Think about like rats on islands, think about the screw worm here in Texas, which is gonna decimate the cattle industry."

"Our solution, which is already made, could eradicate the entire problem in every model that we've done in six to seven months."

The constraint is permitting, not technology.

2. Contrarian Perspectives

Perspective 1: A Founder with Zero Biology Background Running a $12B Biology Company Is a Feature, Not a Bug

Conventional wisdom says deep scientific domain expertise is a prerequisite to leading a frontier science company. Lamm explicitly has none, and frames that as an advantage — it forced Colossal to build end-to-end rather than rely on fragmented academic infrastructure.

"Building this company with no background in Biology" is listed as a podcast topic, and Lamm says on tape: "Our original deck was like, we have no scientist. We have no partnership with Harvard. We have no technologies. And we're a handful of software and hardware people that have no background in biology, and George Church thinks he can make a wooly mammoth, and we're pretty sure that that's worth something. It was pretty bad. I'm being honest, I would've passed on it."

Yet five years later Colossal has produced three sets of live engineered animals, raised $635M, and spun out a $3.8B AI company.

Perspective 2: De-Extinction Funding Is Accretive to Conservation — Not Competitive With It

The dominant criticism from the conservation community is that de-extinction rhetoric weakens the ESA and draws funding away from protecting living species. Lamm's counter is empirical: partner organizations report that their funding went up after Colossal's founding.

"If you go talk to any of our elephant conservation partners, they'll tell you that their funding has gone up since Colossal was invented."

"We argue that 99% of people should keep doing what they are doing with conservation, and we're that 1% difference."

The further claim is that conventional conservation simply cannot keep pace with the rate of loss regardless of funding: "No matter how good conservation works, it just doesn't move at the speed of which we're eradicating species and changing the planet." The forecast backing this: up to 50% of all biodiversity lost in the next 25 years.

Perspective 3: Domain-Specific AI Models Don't Need Frontier-Scale Compute — and That's a Structural Cost Advantage

The consensus view in AI investing is that scale wins: more parameters, more data, more compute. Astromech is built on the opposite premise — a focused model trained on a narrow but uniquely deep dataset (evolutionary and multi-species genomic data) that doesn't compete for the same infrastructure.

"It turns out that Opus doesn't do an ancestral state reconstruction of a genome, and it doesn't build comparative genomics models. So we had to go build all of that."

"It's a very focused model, so it doesn't need the breadth that a lot of these other models need. So we don't have to go build a $500 billion data center in computing power. We don't have to fight for water and other things that people are all upset about."

Internal benchmarks put Astromech's tree-inference method at roughly 100X faster than conventional maximum-likelihood methods at comparable accuracy — suggesting domain-specificity can outperform generalist models at a fraction of the infrastructure cost.

3. Companies Identified

Colossal Biosciences De-extinction and genome engineering company Primary subject of the article. $12B valuation, $635M raised including a $400M round that doubled from its $200M target. 260+ employees, 55,000 sq ft Texas HQ, six species in de-extinction portfolio, three sets of live engineered animals produced.

"We are one of the most undervalued companies in the world."

Astromech AI biology spinout of Colossal, co-founded by Ben Lamm and George Church Raised $20M at $3.8B valuation (up from $2B in March), $60M total. Pre-revenue. Builds predictive models of biological change trained on 3.8 billion years of evolutionary history. Applications span cancer, drug resistance, biosecurity, agriculture, and conservation.

"Biology runs the world and historically, we have only reacted to it. Every genome carries a record of what changed, when it changed, and the tradeoffs that followed, but almost none of that history is readable at scale today."

Form Bio Computational life sciences platform, Colossal spinout Spun out in 2022 with a $30M Series A led by JAZZ Venture Partners. Mentioned as proof of the spinout model producing independent, fundable companies from Colossal's internal tooling.

Breaking Plastic degradation company, Colossal spinout Briefly mentioned alongside Form Bio and Astromech as the second spinout from Colossal's technology portfolio. No valuation or funding disclosed.

Viagen Animal cloning company, acquired by Colossal Cited as the key vertical integration move. Colossal acquired Viagen because it operated at 80% cloning efficiency against the industry standard of 2%, making it essential to the mammoth and de-extinction pipeline.

"Viagen had cloning efficiencies at 80% where most people are at 2%. And so it made sense for us to say, okay, we need to buy them and bolt them on from a vertical integration perspective."

Moderna / Merck (referenced as market context) Pharmaceutical companies Not direct subjects, but cited as evidence of AI × biotech repricing. On August 19, they reported the first positive Phase 3 trial for an AI-designed personalized cancer vaccine; Moderna shares surged a record 177%.

4. People Identified

Ben Lamm Co-Founder & CEO, Colossal Biosciences and Astromech Serial entrepreneur with four prior exits: Chaotic Moon Studios (sold to Accenture, 2015), Team Chaos (sold to Zynga, 2016), Conversable (acquired by LivePerson, 2019), and Hypergiant Industries (AI and space systems for defense). No biology background. Sits on Avi Loeb's UAP scientific advisory board.

"I'm being honest, I would've passed on it." (referring to Colossal's original pitch deck)

George Church Co-Founder, Colossal Biosciences and Astromech; Lead Geneticist Harvard geneticist who helped launch the Human Genome Project. Church is the scientific anchor of both Colossal and Astromech, providing the credentialed scientific foundation that Lamm's operator background does not.

Beth Shapiro Chief Science Officer, Colossal Biosciences Mentioned in the context of scientific criticism. Shapiro has publicly conceded that Colossal's dire wolves are gray wolves carrying 20 edits, not technically resurrected dire wolves — a point that has fueled debate about species labeling and the term "functional de-extinction."

Vincent Lynch Professor, University at Buffalo Cited as a scientific critic. Lynch has called Colossal's species labeling "arrogant," representing the academic community's pushback on whether Colossal's engineered animals constitute true de-extinction.

Bob Nelsen Lead investor, Astromech's $20M round Named as the lead of the most recent Astromech raise. No further detail provided, but his participation signals serious biotech investment credibility.

Avi Loeb Harvard astrophysicist; UAP researcher Mentioned because Lamm sits on his UAP scientific advisory board — a connection that has fueled conspiracy theories about Colossal's genome engineering capabilities being alien-derived, which Lamm denies.

"One of the other conspiracies is that the advancements in genome engineering has come from us studying, which is just not the case, which is just crazy talk."

Thomas Tull, Mark Walter, Jim Breyer Colossal investors Named as representative examples of Colossal's investor profile: long-duration technology capital and impact-oriented funds. No additional detail provided.

Doug Burgum U.S. Interior Secretary Mentioned in the context of policy risk. Burgum has drawn an explicit link between de-extinction rhetoric and weakening the case for the Endangered Species Act — creating a political tension against Colossal's simultaneous MOU with Interior and US Fish and Wildlife Service.

5. Operating Insights

Insight 1: Set Fundraising Targets Below What You Think the Market Will Bear — Then Use Oversubscription as Pricing Intelligence

Every Colossal round has closed at more than 2X the target. Lamm's read on this is that the company has systematically underpriced its capital raises, not just gotten lucky. The implication for founders is that oversubscription is a signal to reprice, not just celebrate.

"I think that we've completely mispriced every single round of capital because every single round of capital has been more than 2X oversubscribed. So what I hear from that is we're cheap. Like, we're a cheap date, and we should raise our rates on capital."

The mechanism that made oversubscription repeatable was consistent delivery against stated milestones:

"It's easy to raise capital when you have trust, and I think trust is built with setting and managing expectations."

Insight 2: Spin Out Technologies That Exceed Your Brand or Mission Perimeter — Don't Force-Fit Them Into the Core

Colossal's spinout model is a deliberate response to a recurring problem: internal R&D generates applications nobody scoped, and folding them into the parent brand creates confusion, dilutes the mission, and destroys the core company's positioning. The answer is equity-preserving spinouts rather than internal expansion.

"We don't know what we don't know, even about the business model."

The practical test Lamm applies: if the application would create brand confusion or require the parent company to do work outside its stated mission boundary, it becomes a spinout. This has now produced three independent, funded companies from a single R&D engine.

Insight 3: Use "Inspiration" as a Hiring and Brand Moat — Make It a Formal Investor Commitment

Colossal made inspiration a stated company objective and a term of its investor agreements from day one, not a marketing afterthought. This created a brand that attracts top scientific talent who want to work on civilization-scale problems, which in turn makes the science better and the subsequent fundraising easier.

"We told our investors this from day one, that inspiration needs to be as important as value creation, and you need to be on board with that."

"How do you take, like, Harvard meets MTV? That was our thesis from day one."

6. Overlooked Insights

Insight 1: Colossal Holds the World's Largest Elephant and Multi-Species Herpesvirus Dataset — and That Data, Not the Animals, Is What Feeds Astromech

EEHV (elephant herpesvirus) kills roughly 20% of baby elephants. Asian elephants get cancer at 2–3% versus 24–25% in humans. Colossal accumulated the largest elephant dataset and largest multi-species herpesvirus dataset in the world as a byproduct of its de-extinction work. These datasets are now Astromech's training foundation — meaning Colossal's conservation biology work is the data moat for its $3.8B AI spinout. This proprietary data-to-AI flywheel is barely discussed but is arguably the most durable competitive advantage in the company's portfolio.

Insight 2: The Artificial Womb Program Has Commercial Inbound From Outside Biotech — Including a Luxury Fiber Buyer and a Middle Eastern Falconry Interest

Colossal has already received unsolicited commercial inbound for technologies it hasn't productized yet. An apparel buyer purchasing billions of units of ethically harvested animal fiber approached Colossal about scaling domestic supply through cloning. A Middle Eastern party expressed interest in Colossal's artificial egg technology for a critically endangered bird tied to falconry culture. Neither of these is on Colossal's official roadmap, and Lamm explicitly flags mission focus as the constraint — not technology or market demand.

"The hardest thing that we will continue to have is making sure that we stay focused on our core mission, and don't deviate too much for some of these large economic opportunities."

This suggests significant unlicensed commercial value sitting on the shelf, waiting for the spinout model to eventually capture it.